Evidence‑Based Pharmacologic Management of Pediatric Allergic Rhinitis

First‑Line Pharmacotherapy

Intranasal corticosteroids are the most effective first‑line medication for children with chronic (persistent) allergic rhinitis, especially in moderate‑to‑severe disease. 1
For mild intermittent or mild persistent allergic rhinitis, second‑generation oral antihistamines (e.g., cetirizine, loratadine, desloratadine, fexofenadine) are appropriate first‑line options. 3
Second‑generation oral antihistamines have an excellent safety profile in children and cause minimal sedation when used at recommended doses. 1
Intranasal antihistamines (azelastine, olopatadine) are equally effective alternatives to oral antihistamines and provide rapid symptom relief within minutes. 4
Intranasal antihistamines are approved for use in children aged ≥ 6 years. 4

In moderate‑to‑severe or persistent allergic rhinitis, intranasal corticosteroids should be initiated as the initial therapy. 1
Intranasal corticosteroids control all four major nasal symptoms—sneezing, itching, rhinorrhea, and congestion—more effectively than other drug classes. 1
They are superior to oral antihistamines, leukotriene‑receptor antagonists, and the combination of those agents. 1
When used at recommended doses, intranasal corticosteroids (fluticasone propionate, mometasone furoate, budesonide) do not produce clinically significant growth suppression in children. 7

Combining an intranasal corticosteroid with an intranasal antihistamine yields superior symptom control compared with either agent alone. 8
This combination is particularly effective in patients aged ≥ 12 years who have an inadequate response to monotherapy. 8
Fixed‑dose combination sprays (azelastine + fluticasone) produce clinically meaningful improvements in total nasal symptom scores. 8
Adding an oral antihistamine to an intranasal corticosteroid does not provide a significant advantage over intranasal corticosteroid monotherapy. 6

For children < 6 years, avoid over‑the‑counter cough and cold products that contain first‑generation antihistamines or decongestants because of safety concerns and reported fatalities. 1
Second‑generation oral antihistamines can be started as early as 2 years of age and maintain an excellent safety profile. 1
Several intranasal corticosteroids are approved for use in children as young as 2 years. 1
In children ≥ 6 years, the full range of treatments—including intranasal antihistamines—are available; intranasal antihistamines provide rapid relief and are useful for episodic symptoms or pre‑exposure prophylaxis. 4

Leukotriene‑receptor antagonists (e.g., montelukast) are less effective than intranasal corticosteroids and no more effective than oral antihistamines; they should be reserved for cases with inadequate response or intolerance to first‑line agents. 3
Depot (parenteral) corticosteroids are contraindicated for recurrent use because of the risk of serious long‑term side effects. 10
Intranasal decongestants should be limited to ≤ 3 days to avoid rhinitis medicamentosa (rebound congestion). 11
Patient adherence is often poor; many patients self‑medicate on‑demand when symptoms are not optimally controlled. Strategies to improve adherence are essential. 6
When administering nasal sprays, direct the spray away from the nasal septum to minimize local adverse effects such as epistaxis and irritation. 1

All statements are supported by peer‑reviewed evidence as indicated by the citation IDs.